Use of cyproterone acetate/ethinylestradiol in polycystic ovary syndrome: rationale and practical aspects

References

• Goodman NF, Cobin RH, Futerweit W, et al. American association of clinical endocrinologists, American college of endocrinology, and androgen excess and PCOS society disease state clinical review: guide to the best practices in the evaluation and treatment of polycystic ovary syndrome – PART 2. Endocrinol Pract. 2015;21:1415–1426.
   PubMed Web of Science ®Google Scholar
• Lizneva D, Suturina L, Walker W, et al. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil Steril. 2016;106:6–15.
   PubMed Web of Science ®Google Scholar
• Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19:41–47.
   PubMed Web of Science ®Google Scholar
• National Institutes of Health. Evidence-based methodology workshop on polycystic ovary syndrome, December 3–5, 2012. Executive summary [Internet]. Available from: https://prevention.nih.gov/docs/programs/pcos/FinalReport.pdf.
   Google Scholar
• Sirmans SM, Pate KA. Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clin Epidemiol. 2014;6:1–13.
   Web of Science ®Google Scholar
• Zafari ZF, Jafarabadi M, Naghizadeh MM, et al. Psychological distress in women with polycystic ovary syndrome from Imam Khomeini Hospital, Tehran. J Reprod Infertil. 2012;13:111–115.
   PubMedGoogle Scholar
• Jones GL, Hall JM, Balen AH, et al. Health-related quality of life measurement in women with polycystic ovary syndrome: a systematic review. Hum Reprod Update. 2008;14:15–25.
   PubMed Web of Science ®Google Scholar
• Azziz R, Marin C, Hoq L, et al. Health care-related economic burden of the polycystic ovary syndrome during the reproductive life span. J Clin Endocrinol Metab. 2005;90:4650–4658.
   PubMed Web of Science ®Google Scholar
• Fauser BCJM, Tarlatzis BC, Rebar RW, et al. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-sponsored 3rd PCOS consensus workshop group. Fertil Steril. 2012;97:28–38.
   PubMed Web of Science ®Google Scholar
• Haoula Z, Salman M, Atiomo W. Evaluating the association between endometrial cancer and polycystic ovary syndrome. Human Reprod. 2012;27:1327–1331.
   PubMed Web of Science ®Google Scholar
• Badawy AS, Elnashar A. Treatment options for polycystic ovary syndrome. Int J Womens Health. 2011;3:25–35.
   PubMedGoogle Scholar
• Poretsky L, Piper B. Insulin resistance, hypersensitivity of LH, and dual defect hypothesis for the pathogenesis of polycystic ovary syndrome. Obstet Gynecol. 1994;84:613–621.
   PubMed Web of Science ®Google Scholar
• McCartney CR, Eagleson CR, Marshall JC. Regulation of gonadotropin secretion: implications for polycystic ovary syndrome. Semin Reprod Med. 2002;20:317–336.
   PubMed Web of Science ®Google Scholar
• Royal College of Obstetricians and Gynecologists. Long-term consequences of Polycystic Ovary Syndrome. Green-top Guideline No. 33. November 2014 [Internet]. Available from: https://www.rcog.org.uk/en/guidelines-research-services/guidelines/gtg33/
   Google Scholar
• Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev. 2012;33:981–1030.
   PubMed Web of Science ®Google Scholar
• Kashanian M, Fazy Z, Pirak A. Evaluation of the relationship between gestational diabetes and a history of polycystic ovarian syndrome. Diabetes Res Clin Pract. 2008;80:289–292.
   PubMed Web of Science ®Google Scholar
• Escobar-Morreale HF, Carmina E, Dewailly D, et al. Epidemiology, diagnosis and management of hirsutism: a consensus statement by the androgen excess and polycystic ovary syndrome society. Hum Reprod Update. 2012;18:146–170.
   PubMed Web of Science ®Google Scholar
• Conn JJ, Jacobs HS, Conway GS. The prevalence of polycystic ovaries in women with type 2 diabetes mellitus. Clin Endocrinol (Oxf). 2000;52:81–86.
   PubMed Web of Science ®Google Scholar
• Peppard HR, Marfori J, Iuorno MJ, et al. Prevalence of polycystic ovary syndrome among premenopausal women with type 2 diabetes. Diabetes Care. 2001;24:1050–1052.
   PubMed Web of Science ®Google Scholar
• Norman RJ, Dewailly D, Legro RS, et al. Polycystic ovary syndrome. Lancet. 2007;370:685–697.
   PubMed Web of Science ®Google Scholar
• Daan N, Koster M, Steegers-Theunissen R, et al. Endocrine and cardiometabolic cord blood characteristics of offspring born to mothers with and without polycystic ovary syndrome. Fertil Steril. 2014;107:261–268.
   Web of Science ®Google Scholar
• Yilmaz SA, Kepapcilar A, Koplay M, et al. Association of clinical androgen excess with radial artery intima media thickness in women with polycystic ovary syndrome. Gynecol Endocrinol. 2015;31:477–482.
   PubMed Web of Science ®Google Scholar
• Naver KV, Grinsted J, Larsen SO, et al. Increased risk of preterm delivery and pre-eclampsia in women with PCOS and hyperandrogenemia. BJOG. 2014;121:575–581.
   PubMed Web of Science ®Google Scholar
• Qin JZ, Pang LH, Li MJ, et al. Obstetric complications in women with PCOS: a systematic review and meta-analysis. Reprod Biol Endocrinol. 2013;11:56.
   PubMed Web of Science ®Google Scholar
• Katulski K, Czyzyk A, Podfigurna-Stopa A, et al. Pregnancy complications in polycystic ovary syndrome patients. Gynecol Endocrinol. 2015;31:87–91.
   PubMed Web of Science ®Google Scholar
• Hickey M, Higham JM, Fraser I. Progestogens with or without oestrogen for irregular uterine bleeding associated with anovulation. Cochrane Database Syst Rev. 2012;(9):CD001895. doi: 10.1002/14651858.CD001895.pub3.
   PubMed Web of Science ®Google Scholar
• Collaborative Group on Epidemiological Studies on Endometrial Cancer. Endometrial cancer and oral contraceptives: an individual participant meta-analysis of 27 276 women with endometrial cancer from 36 epidemiological studies. Lancet Oncol. 2015;16:1061–1070.
   PubMed Web of Science ®Google Scholar
• Hannaford PC, Selvaraj S, Elliot A, et al. Cancer risk among users of oral contraceptives: cohort data from the royal college of general practitioner’s oral contraception study. BMJ. 2007;335:651
   PubMed Web of Science ®Google Scholar
• Yang YM, Choi EJ. Efficacy and safety of metformin or oral contraceptives, or both in polycystic ovary syndrome. Ther Cin Risk Manag. 2015;11:1345–1353.
   PubMed Web of Science ®Google Scholar
• Azziz R, Sanchez L, Knochenhauer ES, et al. Androgen excess in women: experience with over 1000 consecutive patients. J Clin Endocrinol Metab. 2004; 89:453–462.
   PubMed Web of Science ®Google Scholar
• Wijeyaratne CN, Balen AH, Barth JH, et al. Clinical manifestations and insulin resistance (IR) in polycystic ovary syndrome (PCOS) among south Asians and Caucasians: is there a difference?. Clin Endocrinol. 2002;57:343–350.
   PubMed Web of Science ®Google Scholar
• Pace JL. Acne – a potential skin marker of internal disease. Clin Dermatol. 2015;33:572–578.
   PubMed Web of Science ®Google Scholar
• Balen A, Conway G, Kaltsas G. Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients. Hum Reprod. 1995;10:2107–2111.
   PubMed Web of Science ®Google Scholar
• Teede H, Deeks A, Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med. 2010;8:41.
   PubMed Web of Science ®Google Scholar
• Cırık DA, Dilbaz B. What do we know about metabolic syndrome in adolescents with PCOS? J Turk Ger Gynecol Assoc. 2014;15:49–55.
   PubMedGoogle Scholar
• Roe AH, Prochaska E, Smith M, et al. Using the Androgen Excess–PCOS Society criteria to diagnose polycystic ovary syndrome and the risk of metabolic syndrome in adolescents. J Pediatr. 2013;162:937–941.
   PubMed Web of Science ®Google Scholar
• Legro RS, Arslanian SA, Erhmann DA, et al. Diagnosis and treatment of polycystic ovary syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2013;98:4565–4592.
   PubMed Web of Science ®Google Scholar
• Conway G, Dewailly D, Diamanti-Kandarakis E, et al. The polycystic ovary syndrome: a position statement from the European society of endocrinology. Eur J Endocrinol. 2014;171:1–29.
   Web of Science ®Google Scholar
• Lijuan W, Xiangyan R, Yamei C, et al. Analysis of serum anti-mullerian hormone levels in the main phenotypes of polycystic ovary syndrome. J Capital Med Univ. 2016;37:527–531.
   Google Scholar
• Hutchison SK, Stepto NK, Harrison CL, et al. Effects of exercise on insulin resistance and body composition in overweight and obsess women with and without polycystic ovary syndrome. J Clin Endocrinol Metab. 2011;96:E48–E56.
   PubMed Web of Science ®Google Scholar
• Yildiz BO. Oral contraceptives in polycystic ovary syndrome: risk-benefit assessment. Semin Reprod Med. 2008;26:111–120.
   PubMed Web of Science ®Google Scholar
• Buzney E, Sheu J, Buzney E, et al. Polycystic ovary syndrome: a review for dermatologists, part II. Treatment. J Am Acad Dermatol. 2014;71:859.e1–859.e15.
   PubMed Web of Science ®Google Scholar
• Mashchak CA, Lobo RA, Dozono-Takano R, et al. Comparison of pharmacodynamic properties of various estrogen formulations. Am J Obstet Gynecol. 1982;144:511–518.
   PubMed Web of Science ®Google Scholar
• Mandel FP, Geola FL, Lu JKH, et al. Biological effects of various doses of ethinyl estradiol in postmenopausal women. Obstet Gynecol. 1982;59:673–679.
   PubMed Web of Science ®Google Scholar
• Sitruk-Ware R. New progestagens for contraceptive use. Hum Reprod Update. 2006;12:169–178.
   PubMed Web of Science ®Google Scholar
• Neumann F. The antiandrogen cyproterone acetate: discovery, chemistry, basic pharmacology, clinical use and tool in basic research. Exp Clin Endocrinol. 1994;102:1–32.
   PubMedGoogle Scholar
• Schindler Adolf E, Campagnoli C, Druckmann R. et al. Classification and pharmacology of progestins. Maturitas. 2003;46:7–16.
   PubMed Web of Science ®Google Scholar
• Arowojolu AO, Gallo MF, Lopez LM, Grimes DA. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev. 2012;(7):CD004425. doi: 10.1002/14651858.CD004425.pub6.
   Web of Science ®Google Scholar
• Bitzer J, Römer T, Da Silva Lopes A, The use of CPA/EE in hyperandrogenic skin symptoms – a review. 2016.
   Google Scholar
• Dianette Summary of Product Characteristics [Internet]. Available from: http://www.medicines.org.uk/emc/medicine/1814/SPC/dianette/ (last updated 2017).
   Google Scholar
• Rabe T, Bohlmann MK, Rehberger-Schneider S, et al. Non-contraceptive benefits of the pill-an often neglected fact. Gynecol Endocrinol. 2000;14:118–126.
   PubMed Web of Science ®Google Scholar
• Wu H, Ruan X, Jin J, Mueck AO. Metabolic profile of Diane-35 versus Diane-35 plus metformin in Chinese PCOS women under standardized life-style changes. Gynecol Endocrinol. 2015;31:548--551.
   Google Scholar
• Burkman RT. Lipid and lipoprotein changes in relation to oral contraception and hormonal replacement therapy. Fertil Steril. 1988;49:39S–50S.
   PubMed Web of Science ®Google Scholar
• Forthergy K. Oral contraceptives, lipids and cardiovascular disease. Contraception. 1985;31:367–394.
   PubMed Web of Science ®Google Scholar
• Knopp RH, Walden CE, Wahl PW, et al. Effects of oral contraceptives on lipoprotein triglyceride and cholesterol: relationship to estrogen and progestin-potency. Am J Obstet Gynecol. 1982;142:725–731.
   PubMed Web of Science ®Google Scholar
• Lipson A, Stoy DB, LaRosa C, et al. Progestins and oral contraceptive-induced lipoprotein changes: a prospective study. Contraception. 1986;34:121–134.
   PubMed Web of Science ®Google Scholar
• Godsland IFD, Crook R, Simpson T, et al. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N Engl J Med. 1990;323:1375–1381.
   PubMed Web of Science ®Google Scholar
• Spellacy WN. Carbohydrate metabolism during treatment with estrogen, progestogen and low-dose oral contraceptives. Am J Obstet Gynecol. 1982;142:732–734.
   PubMed Web of Science ®Google Scholar
• Gaspard UJ, Lefebvre PJ. Clinical aspects of the relationship between oral contraceptives, abnormalities in carbohydrate metabolism, and the development of cardiovascular disease. Am J Obstet Gynecol. 1990;163:334–343.
   PubMed Web of Science ®Google Scholar
• Loke DFM, Ng CSA, Holck S, et al. Lipid and biochemical changes after los-dose oral contraception. Contraception. 1992;46:227–241.
   PubMed Web of Science ®Google Scholar
• Mattsson LA, Cullberg G, Hamberger L, et al. Lipid metabolism in women with polycystic ovary syndrome: possible implications for an increased risk of coronary heart disease. Fertil Steril. 1984;42:579–584.
   PubMed Web of Science ®Google Scholar
• Wynn V, Godsland I, Niththyananthan R, et al. Comparison of effects of different combined oral-contraceptive formulations on carbohydrate and lipid metabolism. Lancet. 1979;1:1045–1049.
   PubMed Web of Science ®Google Scholar
• Perlman JA, Russel-Briefel R, Ezzati T, et al. Oral glucose tolerance and potency of contraceptive progestins. J Chron Dis. 1985;33:857–864.
   Google Scholar
• Crook D, Godsland IF, Wynn V. Oral contraceptives and coronary heart disease: modulation of glucose tolerance and plasma lipid risk factors by progestins. Am J Obstet Gynecol. 1988;158:1612–1620.
   PubMed Web of Science ®Google Scholar
• Yildiz BO. Approach to the patient: contraception in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2015;100:794–802.
   PubMed Web of Science ®Google Scholar
• de Bastos M, Stegeman BH, Rosendaal FR, et al. Combined oral contraceptives: venous thrombosis. Cochrane Database Syst Rev. 2014;3:CD010813.
   PubMed Web of Science ®Google Scholar
• Shapiro S, Dinger J. Risk of venous thromboembolism among users of oral contraceptives: a review of two recently published studies. Fam Plann Reprod Health Care. 2010;36:33–38.
   PubMed Web of Science ®Google Scholar
• Seaman HE, de Vries CS, Farmer RD. The risk of venous thromboembolism in women prescribed cyproterone acetate in combination with ethinyl estradiol: a nested cohort analysis and case control study. Human Reprod. 2003;18:522–526.
   PubMed Web of Science ®Google Scholar
• Okoroh EM, Hooper C, Atrash HK, et al. Is polycystic ovary syndrome anther risk factor for venous thromboembolism? United States 2003–2008. Am J Obstet Gynecol. 2012;207:377.e1–377.e8.
   PubMed Web of Science ®Google Scholar
• Bird ST, Hartzema AG, Brophy JM, et al. Risk of venous thromboembolism in women with polycystic ovary syndrome: a population-based matched cohort analysis. CMAJ. 2013;185:E115–E120.
   PubMed Web of Science ®Google Scholar
• Yildiz BO, Haznedaroglu IC, Kirazli S, et al. Global fibrinolytic capacity is decreased in polycystic ovary syndrome, suggesting a prothrombotic state. J Clin Endocrinol Metab. 2002;187:3871–3875.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Medical eligibility criteria for contraceptive use. 5th ed. Geneva: WHO; 2015.
   Google Scholar
• Bhattacharya SM, Jha A. Comparative study of the therapeutic effects of oral contraceptive pills containing desogestrel, cyproterone acetate, and drospirenone in patients with polycystic ovary syndrome. Fertil Steril. 2012;98:1053–1059.
   PubMed Web of Science ®Google Scholar
• Cosma M, Swiglo BA, Flynn DN, et al. Clinical review: insulin sensitizers for the treatment of hirsutism: a systematic review and metaanalyses of randomized controlled trials. J Clin Endocrinol Metab. 2008;93:1135–1142.
   PubMed Web of Science ®Google Scholar
• Ruan X, Mueck AO. Oral contraception for women of middle age. Maturitas. 2015;82:266–270.
   PubMed Web of Science ®Google Scholar